AbbVie Inc. (ABBV)
| Market Cap | 296.46B |
| Revenue (ttm) | 55.53B |
| Net Income (ttm) | 5.08B |
| Shares Out | 1.77B |
| EPS (ttm) | 2.87 |
| PE Ratio | 58.45 |
| Forward PE | 14.02 |
| Dividend | $6.56 (3.91%) |
| Ex-Dividend Date | Jan 15, 2025 |
| Volume | 3,019,167 |
| Open | 166.91 |
| Previous Close | 166.57 |
| Day's Range | 165.65 - 167.91 |
| 52-Week Range | 137.65 - 207.32 |
| Beta | 0.61 |
| Analysts | Strong Buy |
| Price Target | 206.00 (+22.79%) |
| Earnings Date | Oct 30, 2024 |
About ABBV
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn’s disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; E... [Read more]
Financial Performance
In 2023, AbbVie's revenue was $54.32 billion, a decrease of -6.44% compared to the previous year's $58.05 billion. Earnings were $4.82 billion, a decrease of -59.09%.
Financial StatementsAnalyst Forecast
According to 21 analysts, the average rating for ABBV stock is "Strong Buy." The 12-month stock price forecast is $206.0, which is an increase of 22.79% from the latest price.
News
My Dividend Stock Portfolio: New October Dividend Record - 100 Holdings With 15 Buys
Investment activity in October focused on Business Development Companies, with $1,300 added to the market. Adjusted dividend income in October of $789, up 25% Y/Y and up 11% sequentially. Main picks i...
Alzamend Neuro Announces Full Data Set from its Nonclinical Study: Comparing Brain and Plasma Lithium Exposures between AL001 and Lithium Carbonate in Alzheimer's Transgenic Mice
ATLANTA--(BUSINESS WIRE)---- $ABBV #Alzamend--Alzamend Neuro Announces Full Data Set from Its Nonclinical Study: Comparing Brain and Plasma Lithium Exposures between AL001 and Lithium Carbonate.
High-Conviction Investing - 4 Of The Best Dividend Stocks Money Can Buy
The current market presents a complex mix of opportunities and risks, influenced by the Trump presidency, Fed policies, and elevated valuations. These factors require careful stock selection. I am foc...
AbbVie Receives European Commission Approval of ELAHERE® (mirvetuximab soravtansine) for the Treatment of Platinum-Resistant Ovarian Cancer
ELAHERE is the first and only novel therapy approved in the European Union specifically for patients with folate receptor-alpha (FRα) positive, platinum-resistant ovarian cancer ELAHERE represents the...
Final Trades: Bitcoin, Abbvie and Baker Hughes
The Investment Committee reveals their final trades for today.
AbbVie Awards 20 Individuals Living With Migraine To Support Career Aspirations
AbbVie Migraine Career Catalyst Award™ contest winners shared inspiring stories and professional goals, showcasing their triumphs over the challenges of living with migraine AbbVie, a leader in migrai...
Aldeyra's FDA Resubmission And AbbVie Option Revitalize Reproxalap's Prospects
Aldeyra received an FDA CRL for reproxalap, necessitating an additional study for DED approval. AbbVie entered an option agreement with Aldeyra, potentially licensing reproxalap for global markets. Al...
AbbVie's Schizophrenia Failure Disappoints But Analysts Show Confidence In Immunology Portfolio
On Monday, AbbVie Inc ABBV stock plunged after two trials investigating emraclidine as a once-daily, oral monotherapy treatment for adults with schizophrenia failed two Phase 2 trials.
AbbVie's disappointing schizophrenia drug trial bodes well for rival Bristol Myers, analysts say
AbbVie's “pain” is Bristol Myers Squibb's “gain,” says Truist Securities analyst Srikripa Devarakonda.
Buy, Sell, Or Hold AbbVie Stock?
AbbVie stock (NYSE: ABBV) was down 12% on Monday, November 11, after the company announced that two mid-stage clinical trials of its drug Emraclidine to treat schizophrenia failed to meet their primar...
Final Trades: Lyft, Meta, United States Oil Fund & Abbvie
AbbVie And Pfizer: Q3 Dividend Checkup Post-Earnings
I review both AbbVie and Pfizer's recent earnings reports via the window of dividends following Peter Lynch's wisdom. Lynch's insights into dividend stocks are often in the shadow of his reputation as...
Best Stocks to Buy for a Fed Rate Cut
Consider these stock and fund picks now that the Federal Reserve's rate-cutting campaign is underway.
Is AbbVie Still A Strong Buy After Fantastic Gains? (Rating Downgrade)
AbbVie investors that bought the anxiety over the loss of Humira exclusivity are sitting on massive gains. There are three significant reasons for optimism from here. However, the dividend yield is ne...
AbbVie Stock: Keep Calm And Buy The Dip
AbbVie shares dropped nearly 10% after its schizophrenia drug emraclidine failed in late-stage trials. The market reaction appears excessive and presents a buying opportunity. Dividend yield and robus...
AbbVie stock drops 12% on schizophrenia drug setback: should you buy the dip?
AbbVie Inc (NYSE: ABBV) saw its stock fall nearly 13% after reporting disappointing mid-stage trial results for emraclidine, an experimental treatment for schizophrenia. This setback is notable as Abb...
Trade Tracker: Jim Lebenthal buys more Abbvie
Jim Lebenthal, chief equity strategist at Cerity Partners, joins CNBC's 'Halftime Report' to discuss why he's buying more of the pharma stock on this dip.
AbbVie's Emraclidine For Schizophrenia 'Surprisingly Disappoints,' Analyst Says Pipeline Is Underappreciated
On Monday, AbbVie Inc ABBV stock plunged after two trials investigating emraclidine as a once-daily, oral monotherapy treatment for adults with schizophrenia failed two Phase 2 trials.
AbbVie Stock Sinks After Schizophrenia Drug Trials Disappoint
Shares of AbbVie (ABBV) plummeted Monday after the company said its schizophrenia drug Emraclidine missed key goals in a pair of Phase 2 clinical trials.
AbbVie: Emraclidine's Failure Eliminates An Important Growth Driver
Emraclidine's failure in phase 2 trials is a significant setback for AbbVie's neuroscience pipeline. This was a very surprising outcome after very strong phase 1b results and the success of competitor...
AbbVie Stock Slips As $9 Billion Schizophrenia Studies Flunk, Bristol-Myers Stock Surges
On Monday, AbbVie Inc ABBV stock is trading lower after it released data from its two Phase 2 EMPOWER trials of emraclidine for schizophrenia.
AbbVie Stock Falls Sharply as Schizophrenia Therapy Shows No ‘Significant' Improvement
Two trials of the company's experimental schizophrenia drug show no significant improvement in symptoms.
AbbVie's schizophrenia drug misses main goals of two trials
AbbVie said on Monday its experimental schizophrenia drug failed to meet the main goal of two mid-stage trials, sending its shares down more than 11% in premarket trading.
AbbVie Provides Update on Phase 2 Results for Emraclidine in Schizophrenia
EMPOWER-1 and EMPOWER-2 Phase 2 clinical trials did not meet their primary endpoint Emraclidine was well-tolerated with an adverse event profile consistent with Phase 1b trial NORTH CHICAGO, Ill. , No...
Top 3 stocks to buy after Fed's 25-basis-point rate cut
US stocks remain resilient following the Federal Reserve's decision to lower its key interest rate by another 25 basis points on Thursday. According to the post-meeting statement: The Committee judges...